CA2898878C - Enhanced transgene expression and processing - Google Patents
Enhanced transgene expression and processing Download PDFInfo
- Publication number
- CA2898878C CA2898878C CA2898878A CA2898878A CA2898878C CA 2898878 C CA2898878 C CA 2898878C CA 2898878 A CA2898878 A CA 2898878A CA 2898878 A CA2898878 A CA 2898878A CA 2898878 C CA2898878 C CA 2898878C
- Authority
- CA
- Canada
- Prior art keywords
- mar
- seq
- expression
- tep
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759802P | 2013-02-01 | 2013-02-01 | |
| US61/759,802 | 2013-02-01 | ||
| US201361800244P | 2013-03-15 | 2013-03-15 | |
| US61/800,244 | 2013-03-15 | ||
| US201361806634P | 2013-03-29 | 2013-03-29 | |
| US61/806,634 | 2013-03-29 | ||
| PCT/IB2014/000100 WO2014118619A2 (en) | 2013-02-01 | 2014-02-01 | Enhanced transgene expression and processing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2898878A1 CA2898878A1 (en) | 2014-08-07 |
| CA2898878C true CA2898878C (en) | 2020-04-28 |
Family
ID=50239688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2898878A Active CA2898878C (en) | 2013-02-01 | 2014-02-01 | Enhanced transgene expression and processing |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11898154B2 (enExample) |
| EP (2) | EP2951309B1 (enExample) |
| JP (1) | JP6563816B2 (enExample) |
| KR (1) | KR102235603B1 (enExample) |
| CN (2) | CN120718957A (enExample) |
| AU (2) | AU2014210856B2 (enExample) |
| CA (1) | CA2898878C (enExample) |
| DK (2) | DK2951309T3 (enExample) |
| ES (2) | ES2717175T3 (enExample) |
| FI (1) | FI3536797T3 (enExample) |
| HU (2) | HUE061494T2 (enExample) |
| IL (1) | IL240198B (enExample) |
| LT (1) | LT2951309T (enExample) |
| PL (2) | PL3536797T3 (enExample) |
| PT (2) | PT3536797T (enExample) |
| RU (1) | RU2711505C9 (enExample) |
| SG (2) | SG11201505487UA (enExample) |
| SI (1) | SI2951309T1 (enExample) |
| WO (1) | WO2014118619A2 (enExample) |
| ZA (1) | ZA201506419B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109576265B (zh) * | 2014-04-01 | 2020-08-28 | 三生国健药业（上海）股份有限公司 | 一种含mar核心片段的动物细胞表达载体 |
| CN105154473B (zh) * | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合系统及其用途 |
| JP6871679B2 (ja) * | 2016-03-23 | 2021-05-12 | 国立大学法人 岡山大学 | 遺伝子発現用カセット及びその産生物 |
| WO2017061354A1 (ja) * | 2015-10-06 | 2017-04-13 | 国立大学法人 岡山大学 | 遺伝子発現用カセット及びその産生物 |
| JP2017070224A (ja) * | 2015-10-06 | 2017-04-13 | 国立大学法人 岡山大学 | 遺伝子発現用カセット及びその産生物 |
| SG11201805132YA (en) | 2015-12-24 | 2018-07-30 | Selexis Sa | Improved eukaryotic cells for protein manufacturing and methods of making them |
| ITUA20161610A1 (it) * | 2016-03-14 | 2017-09-14 | Angela Anna Messina | Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso. |
| EP3219800A1 (en) * | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| EP3219803A1 (en) * | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum für Molekulare Medizin | Enhanced sleeping beauty transposons, kits and methods of transposition |
| JP6959942B2 (ja) * | 2016-05-03 | 2021-11-05 | ロンザ リミテッドLonza Limited | タンパク質生成のための脂質代謝のモジュレーション |
| CN109790539A (zh) * | 2016-10-03 | 2019-05-21 | 第一三共株式会社 | Hspa5基因的启动子 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102523318B1 (ko) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법 |
| WO2018224162A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for characterizing loss of antigen presentation |
| JP7240749B2 (ja) * | 2017-09-29 | 2023-03-16 | ベスファジェン・インコーポレイテッド | 心不全の予防または治療のための医薬組成物 |
| CN109929839B (zh) * | 2017-12-18 | 2021-02-12 | 华东师范大学 | 拆分型单碱基基因编辑系统及其应用 |
| CN108504692B (zh) * | 2018-03-26 | 2021-07-23 | 安徽大学 | 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用 |
| EP3794128A1 (en) * | 2018-05-18 | 2021-03-24 | Sorbonne Universite | Molecular tools and methods for transgene integration and their transposition dependent expression |
| EP3810764A2 (en) | 2018-06-21 | 2021-04-28 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| RU2686102C1 (ru) * | 2018-08-07 | 2019-04-24 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов |
| EP3847261A1 (en) * | 2018-09-05 | 2021-07-14 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | A method for engineering synthetic cis-regulatory dna |
| US20210380661A1 (en) * | 2018-10-16 | 2021-12-09 | Texas Tech University System | Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes |
| WO2020084528A1 (en) | 2018-10-24 | 2020-04-30 | Selexis Sa | Expression systems, recombinant cells and uses thereof |
| US12404527B2 (en) * | 2018-12-24 | 2025-09-02 | Selexs S.A. | Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells |
| US20220088158A1 (en) | 2019-01-23 | 2022-03-24 | Aceragen, Inc. | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
| IT201900002321A1 (it) * | 2019-02-18 | 2020-08-18 | Univ Degli Studi Padova | Peptidi con attivita' antitumorale |
| EP3946596A4 (en) * | 2019-03-27 | 2022-12-21 | Phoenix Tissue Repair, Inc. | SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7 |
| CN110006866B (zh) * | 2019-04-16 | 2022-04-22 | 杭州迈尔德生物科技有限公司 | 一种阿片类活性物质的通用检测方法及其检测试剂盒 |
| WO2020228721A1 (en) * | 2019-05-13 | 2020-11-19 | Lin Mei Chun | Method and kit for monitoring cancer |
| CN114514324A (zh) * | 2019-10-10 | 2022-05-17 | 加利福尼亚州立大学董事会 | 稳定哺乳动物细胞的方法 |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| CN112813099A (zh) * | 2019-11-15 | 2021-05-18 | 上海细胞治疗集团有限公司 | 一种在活化的t细胞中具有高活性的启动子 |
| CN110863008B (zh) * | 2019-11-22 | 2020-10-16 | 昆明学院 | Mar序列调控弱启动子构建高效表达载体的方法 |
| AU2020412891A1 (en) | 2019-12-24 | 2022-06-30 | Selexis Sa | Targeted integration in mammalian sequences enhancing gene expression |
| BR112022016617A2 (pt) * | 2020-02-19 | 2022-11-22 | Wuxi Biologics Ireland Ltd | Ácido nucleico, vetor, vetor de transposon, sistema de expressão, ácido nucleico isolado, método para gerar uma célula, célula, método de expressão de uma proteína, proteína, composiçao farmacêutica, sistema de expressão, linhagem celular |
| CN111500629B (zh) * | 2020-04-17 | 2021-11-19 | 安徽中盛溯源生物科技有限公司 | 一种高表达层粘连蛋白-511变体的方法及其应用 |
| EP4149966A4 (en) * | 2020-05-14 | 2024-08-07 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | DOUBLE PROMOTOR SYSTEMS |
| US12173304B2 (en) * | 2020-07-08 | 2024-12-24 | Neuracle Genetics Inc. | Intron fragments |
| CN113881703B (zh) * | 2021-10-11 | 2022-06-21 | 中国人民解放军军事科学院军事医学研究院 | 一种提高cho细胞同源重组效率的方法及其相关产品和应用 |
| CN116440269B (zh) * | 2022-01-10 | 2024-02-09 | 华中农业大学 | Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用 |
| CN114958914B (zh) * | 2022-06-06 | 2023-09-26 | 新乡医学院 | 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用 |
| CN115896227A (zh) * | 2022-12-20 | 2023-04-04 | 西北农林科技大学 | 一种鉴定外源基因整合位点以增强转基因表达的方法 |
| GB202305637D0 (en) | 2023-04-17 | 2023-05-31 | Macomics Ltd | Transposons, vectors and genetically engineered cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731178A (en) | 1990-03-21 | 1998-03-24 | Behringwerke Aktiengesellschaft | Attachment-elements for stimulation of eukaryotic expression systems |
| JP3656277B2 (ja) * | 1995-05-17 | 2005-06-08 | 味の素株式会社 | 組換えｄｎａ法によるトランスグルタミナーゼの効率的製造法 |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| US20040235011A1 (en) * | 2002-06-26 | 2004-11-25 | Cooper Richard K. | Production of multimeric proteins |
| US20040203158A1 (en) * | 2003-01-15 | 2004-10-14 | Hackett Perry B. | Transposon-insulator element delivery systems |
| US7244616B2 (en) * | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
| IN2014DN02484A (enExample) | 2003-10-24 | 2015-05-15 | Selexis Sa | |
| ES2292271B1 (es) * | 2004-05-20 | 2009-02-16 | Proyecto De Biomedicina Cima, S.L. | Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales. |
| WO2007021353A2 (en) * | 2005-06-10 | 2007-02-22 | Genentech, Inc. | Improving antibody expression using vectors containing insulator elements |
| CN101855233B (zh) | 2007-09-26 | 2014-05-07 | 英特瑞克斯顿股份有限公司 | 合成5’utr、表达载体以及增强转基因表达的方法 |
| US20090247609A1 (en) | 2007-12-20 | 2009-10-01 | Hitto Kaufmann | Sm-protein based secretion engineering |
| US20100105140A1 (en) * | 2008-07-16 | 2010-04-29 | Fahrenkrug Scott C | Plaice dna transposon system |
| EP2417263B1 (en) * | 2009-04-09 | 2015-09-23 | ProteoVec Holding L.L.C. | Production of proteins using transposon-based vectors |
| JP2013505013A (ja) * | 2009-09-18 | 2013-02-14 | セレクシス エス．エー． | 強化導入遺伝子発現およびプロセッシングの産物および方法 |
-
2014
- 2014-02-01 ES ES14708935T patent/ES2717175T3/es active Active
- 2014-02-01 CN CN202510831703.7A patent/CN120718957A/zh active Pending
- 2014-02-01 WO PCT/IB2014/000100 patent/WO2014118619A2/en not_active Ceased
- 2014-02-01 ES ES19153376T patent/ES2940433T3/es active Active
- 2014-02-01 HU HUE19153376A patent/HUE061494T2/hu unknown
- 2014-02-01 EP EP14708935.3A patent/EP2951309B1/en active Active
- 2014-02-01 PL PL19153376.9T patent/PL3536797T3/pl unknown
- 2014-02-01 LT LTEP14708935.3T patent/LT2951309T/lt unknown
- 2014-02-01 EP EP19153376.9A patent/EP3536797B1/en active Active
- 2014-02-01 SG SG11201505487UA patent/SG11201505487UA/en unknown
- 2014-02-01 KR KR1020157022393A patent/KR102235603B1/ko active Active
- 2014-02-01 PT PT191533769T patent/PT3536797T/pt unknown
- 2014-02-01 AU AU2014210856A patent/AU2014210856B2/en active Active
- 2014-02-01 PT PT14708935T patent/PT2951309T/pt unknown
- 2014-02-01 JP JP2015555816A patent/JP6563816B2/ja active Active
- 2014-02-01 DK DK14708935.3T patent/DK2951309T3/en active
- 2014-02-01 SI SI201431115T patent/SI2951309T1/sl unknown
- 2014-02-01 PL PL14708935T patent/PL2951309T3/pl unknown
- 2014-02-01 DK DK19153376.9T patent/DK3536797T5/da active
- 2014-02-01 FI FIEP19153376.9T patent/FI3536797T3/fi active
- 2014-02-01 HU HUE14708935A patent/HUE043103T2/hu unknown
- 2014-02-01 RU RU2015127667A patent/RU2711505C9/ru active
- 2014-02-01 CA CA2898878A patent/CA2898878C/en active Active
- 2014-02-01 CN CN201480010305.9A patent/CN105073995A/zh active Pending
- 2014-02-01 US US14/761,460 patent/US11898154B2/en active Active
- 2014-02-01 SG SG10201803758XA patent/SG10201803758XA/en unknown
-
2015
- 2015-07-28 IL IL24019815A patent/IL240198B/en active IP Right Grant
- 2015-09-01 ZA ZA2015/06419A patent/ZA201506419B/en unknown
-
2019
- 2019-10-18 AU AU2019250224A patent/AU2019250224B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2898878C (en) | Enhanced transgene expression and processing | |
| US10760081B2 (en) | Compositions and methods for enhancing CRISPR activity by POLQ inhibition | |
| US20120231449A1 (en) | Products and methods for enhanced transgene expression and processing | |
| Ley et al. | MAR elements and transposons for improved transgene integration and expression | |
| US9551009B2 (en) | Transcription unit and use thereof in expression vectors | |
| WO2013006142A1 (en) | A novel process and reagent for rapid genetic alterations in eukaryotic cells | |
| EP3201337A1 (en) | Methods and compositions for use of non-coding rna in cell culturing and selection | |
| WO2018150345A1 (en) | An expression vector | |
| HK40007175B (en) | Enhanced transgene expression and processing | |
| RU2808756C1 (ru) | Улучшенные экспрессия и процессинг трансгена | |
| HK40007175A (en) | Enhanced transgene expression and processing | |
| HK1216323B (en) | Enhanced transgene expression and processing | |
| WO2017078461A1 (ko) | 목적 단백질 생산을 위한 발현 벡터 및 이를 이용한 목적 단백질의 과발현 방법 | |
| US9512230B2 (en) | Transcription units and the use thereof in expression vectors | |
| US20250320526A1 (en) | Method for production of a eukaryotic host cell or cell line for lambda-integrase-mediated recombination | |
| Michael | Localization of Line-1 ORF1p in 3D Cultures and Generation of an ORF1p Knockdown Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170125 |